The hyperactivation has been linked to genetic mutations related to this pathway, including CTNNB1 (11–37% of HCC cases), AXIN1 (10% of HCC cases), APC (less than 2% of HCC cases), and ZNRF3 (3% of HCC cases) [41]. The gene discussed is ZNRF3; the disease is hepatocellular carcinoma.